Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
10x Genomics Inc (TXG)
NASDAQ:TXG
Holding TXG?
Track your performance easily
TXG Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.95 - $51.22
Previous CloseN/A
Volume385.49K
Average Volume (3M)1.77M
Market Cap
$1.83B
Enterprise Value$2.41B
Total Cash (Recent Filing)$47.86M
Total Debt (Recent Filing)$6.33M
Price to Earnings (P/E)―
Beta1.97
Next Earnings
Feb 12, 2025EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.53
Shares Outstanding106,997,610
10 Day Avg. Volume2,052,038
30 Day Avg. Volume1,767,558
Standard Deviation0.17
R-Squared0.32
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.88
Price to Cash Flow (P/CF)21.00
P/FCF Ratio25.50
Enterprise Value/Market Cap1.32
Enterprise Value/Revenue3.83
Enterprise Value/Gross Profit5.90
Enterprise Value/Ebitda-18.42
Forecast
1Y Price Target
$19.70Price Target Upside30.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
10x Genomics News
Bulls Say, Bears Say
Bulls Say
EarningsTXG announced preliminary 4Q24 results that beat expectations and guidance, with total revenue of ~$165mn coming in above consensus of $153.4mn.
Market PositionTXG's single-cell portfolio and spatial products remain number one in the market despite disruptions, offering the best combination of performance and price.
Product DemandA 20% sequential growth in spatial consumables suggests healthier demand, driven by new products like Visium HD and Xenium Prime 5K.
Bears Say
Commercial ChallengesA major sales force overhaul has caused disruption, with 40% of US accounts having a new sales representative and 44 open commercial/sales positions.
Financial GuidanceThe company lowered its 2024 revenue guidance, reflecting soft 4Q performance.
Market CompetitionTXG's near-term outlook does not appear favorable amid self-imposed factors and external issues (including competition) hindering performance.
---
Ownership Overview
2.09% Insiders
27.21% Mutual Funds
1.96% Other Institutional Investors
46.18% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TXG FAQ
What was 10x Genomics Inc’s price range in the past 12 months?
10x Genomics Inc lowest stock price was $12.95 and its highest was $51.22 in the past 12 months.
What is 10x Genomics Inc’s market cap?
10x Genomics Inc’s market cap is $1.83B.
When is 10x Genomics Inc’s upcoming earnings report date?
10x Genomics Inc’s upcoming earnings report date is Feb 12, 2025 which is in 25 days.
How were 10x Genomics Inc’s earnings last quarter?
10x Genomics Inc released its earnings results on Oct 29, 2024. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.329 by $0.029.
Is 10x Genomics Inc overvalued?
According to Wall Street analysts 10x Genomics Inc’s price is currently Undervalued.
Does 10x Genomics Inc pay dividends?
10x Genomics Inc does not currently pay dividends.
What is 10x Genomics Inc’s EPS estimate?
10x Genomics Inc’s EPS estimate is -0.3.
How many shares outstanding does 10x Genomics Inc have?
10x Genomics Inc has 106,997,610 shares outstanding.
What happened to 10x Genomics Inc’s price movement after its last earnings report?
10x Genomics Inc reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.329. Following the earnings report the stock price went up 4.433%.
Which hedge fund is a major shareholder of 10x Genomics Inc?
Among the largest hedge funds holding 10x Genomics Inc’s share is ARK Investment Management LLC. It holds 10x Genomics Inc’s shares valued at 243M.
---
10x Genomics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$19.70 (30.55% Upside)
$19.70 (30.55% Upside)
Blogger Sentiment
Bearish
TXG Sentiment 67%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 2.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $171.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 5.8%
Last 30 Days ▲ 5.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.09%
12-Months-Change
Fundamentals
Return on Equity
-24.87%
Trailing 12-Months
Asset Growth
-1.13%
Trailing 12-Months
Company Description
10x Genomics Inc
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company's products include Single Cell Gene Expression, Immune Profiling, CNV, ATAC, and Genome and Exome. 10X Genomics was founded by Serge Saxonov, Ben Hindson, Kevin D. Ness and Eduard Diviu Terradas on July 2, 2012 and is headquartered in Pleasanton, CA.
---
TXG Company Deck
---
TXG Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Negative
While the company made strides in improving gross margins and saw significant growth in spatial consumables, it faced challenges with declining overall revenue, sales restructuring disruptions, and cautious customer spending. The sentiment is tempered by the strong spatial consumables performance but overshadowed by the revenue decline and sales restructuring issues.Read More>---
TXG Revenue Breakdown
60.32% Americas
22.99% EMEA
8.45% Asia-Pacific excluding China
8.24% China
---
TXG Stock 12 Month Forecast
Average Price Target
$19.70
▲(30.55% Upside)
Technical Analysis
Pacific Biosciences
―
Twist Bioscience
―
Fate Therapeutics
―
Crispr Therapeutics AG
―
Intellia Therapeutics
―
Beam Therapeutics
―
Best Analysts Covering TXG
1 Year
1 Year Success Rate
8/17 ratings generated profit
1 Year Average Return
+6.64%
reiterated a buy rating 7 days ago
Copying Patrick B Donnelly's trades and holding each position for 1 Year would result in 47.06% of your transactions generating a profit, with an average return of +6.64% per trade.
---